Superstar Uplisters

[MikeDDKing]

AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT
Company Announces One-for-Fifty Reverse Stock Split
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis onAugust 07, 2015

SAN DIEGO & RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY--(BUSINESS WIRE)--

AmpliPhi BioSciences Corporation (APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its board of directors has approved a one-for-fifty reverse split of the company’s common stock to become effective at market open on August 07, 2015. The company has also been cleared to submit an application to the NYSE MKT for a planned uplisting. AmpliPhi’s eligibility is subject to NYSE MKT rules and regulations and maintaining a minimum market price per share for a specified time period as determined by the NYSE.

“We believe that the reverse stock split will facilitate our listing to a major national exchange, and by listing on a national exchange we will significantly increase the marketability of the company’s common stock among both institutional and retail investors focused on national exchange-listed securities,” said M. Scott Salka, CEO of AmpliPhi. “Following our recent successful financing round in March 2015, AmpliPhi remains in a solid financial position to execute on its near-term corporate objectives and we expect that the reverse split will encourage greater interest in our Common Stock by the financial community and the investing public.”

The reverse stock split was authorized by shareholders on August 03, 2015 at the Company’s 2015 Annual Meeting. The reverse stock split is intended to increase the per share trading price of the company’s common stock to meet the minimum per share bid price required by NYSE MKT. The effect of the reverse stock split will be to combine each 50 shares of outstanding common stock into one new share, with no change in par value per share, and to reduce the number of common shares outstanding from approximately 289 million to approximately 5.8 million. On August 07, 2015, the Company’s stock will trade on the OTCQB under the symbol “APHBD”, with the “D” added to signify a reverse stock split has occurred.

Informational letters will be sent to all shareholders on record by the Company’s transfer agent, Computershare. Additional information about the reverse stock split can be found in the Company’s Form 8-K filed today with the Securities and Exchange Commission.

About AmpliPhi BioSciences

AmpliPhi BioSciences Corporation (APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. The Company's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (XON), the U.S. Army, The Royal Brompton Clinic in London and The University of Leicester, UK to rapidly advance bacteriophage-based therapies.

For more information, visit www.ampliphibio.com.

About Bacteriophage

Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defence for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.

Forward Looking Statements

Statements in this press release about the potential listing of the Company’s common stock on the NYSE MKT, potential improvements in the marketability of the Company’s securities, the ability of the Company to execute on its near term objectives, the potential use of bacteriophages to treat bacterial infections, including infections in biofilms and infections that do not respond to antibiotics, and the development of bacteriophage-based therapies are forward looking statements subject to risks and uncertainties, including without limitation the risk that the Company will not satisfy the listing criteria of the NYSE MKT, that the trading price of the Company’s common stock may decline following the reverse split, that the Company will not be able to successfully manufacture sufficient quantities of products to conduct clinical trials or commercialize products in a timely manner or at all, that AmpliPhi may not commence clinical trials or complete IND-enabling studies as expected, that the clinical trials will not be successful, that further development of the Company's products will require extensive and expensive nonclinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to AmpliPhi's business in general, see AmpliPhi's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as amended, filed with the Securities and Exchange Commission (SEC) on April 15, 2015.


View source version on businesswire.com: http://www.businesswire.com/news/home/20150804005466/en/

Contact:
Company and Investor relations:
AmpliPhi BioSciences Corporation
Baxter Phillips III
Chief Business Officer
[phone]
[e-mail]
or
Media relations (USA)
Lazar Partners
Danielle Lewis/Glenn Silver
[phone]
[e-mail]
or
Media Relations (Europe and ROW)
Instinctif Partners
Gemma Howe/Sue Charles
[phone]
[e-mail]

[Mermelstein]

I really like PYDS. Profitable, growing, and in a hot industry (payments).

[MikeDDKing]

Payment Data Systems Announces Approval for Listing on NASDAQ
Begins Trading on the NASDAQ Capital Market on August 11, 2015

SAN ANTONIO, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Payment Data Systems, Inc. (OTCQB:PYDSD) (PYDS), announced that it has received confirmation that its application to list the Company's common stock on the NASDAQ Capital Market has been approved by The NASDAQ Stock Market, a unit of the NASDAQ OMX Group. In honor of the listing, the Company will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York City, on Monday, December 21, 2015

The Company's common stock is expected to begin trading on NASDAQ at the opening of trading on August 11, 2015 under the ticker symbol, PYDSD. The Company's common stock will continue to trade on the OTCBB and the OTCQB until market close on August 10, 2015 under the ticker symbol, PYDSD.

After 20 days, or on August 20, the Company's ticker symbol will revert to trading as PYDS from PYDSD on NASDAQ.

Michael Long, Chairman and CEO of Payment Data Systems stated, "Our listing on the NASDAQ Capital Market is a major corporate milestone for our Company and a testament to the tremendous progress we have made over the past few years. Furthermore, we believe that the listing on NASDAQ will help broaden our shareholder base, increase appeal to institutional investors, provide us with better liquidity and ultimately contribute to increasing shareholder value."

About Payment Data Systems, Inc.

Payment Data Systems is an integrated payment solutions provider to merchants and billers. The Company provides an extensive set of products to deliver world-class payment acceptance. Payment Data has solutions for merchants, billers, banks, service bureaus and card issuers. The strength of the Company is its ability to offer specifically tailored solutions for card issuance, payment acceptance and bill payments.

Through its wholly-owned subsidiary of FiCentive, Inc., a turn-key prepaid card solutions provider, that quickly and securely delivers customized prepaid card programs for corporations, financial institutions, affinity groups or any organization that needs to deliver a financial incentive to their customers, vendors, or employees.

The Company's proprietary platform boasts the highest level of security, encryption and card association compliance. The Company's prepaid card programs for many industries.

For additional information, visit www.paymentdata.com. Contact Michael Long for Investor Relations information at 210.249.4040 or email at [e-mail].

Websites: www.paymentdata.com, www.ficentive.com, www.zbill.com

Find us on Facebook(R)

FORWARD-LOOKING STATEMENTS DISCLAIMER:

Except for the historical information contained herein, the matters discussed in this release include certain forward-looking statements, which are intended to be covered by safe harbors. Those statements include, but may not be limited to, all statements regarding our and management's intent, belief and expectations, such as statements concerning our future and our operating and growth strategy. Investors are cautioned that all forward-looking statements involve risks and uncertainties including, without limitation, the factors detailed from time to time in our filings with the Securities and Exchange Commission. One or more of these factors have affected, and in the future could affect our businesses and financial results in the future and could cause actual results to differ materially from plans and projections. We believe that the assumptions underlying the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. All forward-looking statements made in this release are based on information presently available to our management. We assume no obligation to update any forward-looking statements, except as required by law.

Contact:

[MikeDDKing]

XELB to uplist.

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10830644-1048-5270&type=sect&TabIndex=2&companyid=61156&ppu=%252fdefault.aspx%253fcik%253d1083220

[MikeDDKing]

Kirin International Submits Application to Trade on NASDAQ

NEW YORK, July 30, 2015 (GLOBE NEWSWIRE) -- Kirin International Holdings Inc. (KIRI) (the "Company"), a non-state-owned real estate development company focused on residential and commercial real estate development in "tier-three" cities in the People's Republic of China, today announced the Company has submitted an initial listing application to the NASDAQ Stock Market to have its common stock approved for listing on the NASDAQ Capital Market. The NASDAQ Stock Market is an American stock exchange which is the second-largest exchange in the world by market capitalization.

Jianfeng Guo, Chief Executive Officer, President and Director of the Company, stated, "Having elected two independent directors to serve on our board and after tax net income expected to reach US$10.00 million in 2015, we are moving forward to uplist on a major international stock exchange in order to provide our current and prospective shareholders with the greater trading liquidity available on an international exchange. We submitted our application to NASDAQ in May 2015."

The Company cannot assure that the listing will be approved.

ABOUT KIRIN INTERNATIONAL HOLDING, INC.

Kirin is a Nevada corporation that operates through its wholly-owned subsidiary, Kirin China, a non-state-owned real estate development company focused on residential and commercial real estate development in "tier-three" cities in the People's Republic of China ("PRC"). Tier-three cities are provincial capital cities with ordinary economic development and prefecture cities with relatively strong economic development. Kirin China's projects are currently concentrated in Hebei Province of the PRC, primarily in the city of Xingtai, and nearby regions. Hebei Province is located in the North Region of the PRC. Kirin China intends to also focus on the Bohai Sea Surrounding Area, which comprises Beijing, Tianjin, Hebei Province, Liaoning Province and Shandong Province

FORWARD-LOOKING STATEMENTS

This release contains "forward-looking statements" under the federal securities laws. Forward-looking statements, which contain words such as "expect," "intend, "believe," or "plan," by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

Contact:
Kirin International Holdings
Larry Liu
Vice President
[e-mail]
PCG Advisory
Investors:
Kirin Smith, Chief Operating Officer
[e-mail]
D: + 1 646-863-6519
Media:
Sean Leous, Chief Communications Officer
[e-mail]
D: + 1 646-863-8998

[MikeDDKing]

SITO Mobile Completes 1-for-10 Reverse Stock Split in Preparation for Uplisting to NASDAQ

JERSEY CITY, N.J., July 30, 2015 (GLOBE NEWSWIRE) -- SITO Mobile Ltd. (SITO) (OTCQB:SITOD), a leading mobile engagement platform provider, announced today that it has effected a 1-for-10 reverse split of its issued and outstanding common stock (the "Reverse Split"), which will be effective July 30, 2015 as a key step in preparation for its planned uplisting to the NASDAQ Capital Market.

"This transaction helps us meet the stock price criteria for our planned uplisting to Nasdaq. We are pleased to have completed the reverse stock split, which we believe will generate better liquidity and attract more investors to our story," said Jerry Hug, CEO of SITO Mobile.

As of today, the Company's common stock will begin trading on a post-split basis, under the symbol "SITOD," with the "D" added for 20 trading days to signify that a reverse stock split has occurred. A new CUSIP number 82988R203 has been assigned to the Company's common stock as a result of the reverse split.

Following the reverse split, every ten shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock with a par value of $0.001 per share. The total issued and outstanding common shares will be reduced from approximately 163.42 million shares to approximately 16.34 million, subject to adjustment for fractional shares. No fractional shares are to be issued.

About SITO Mobile Ltd.

SITO Mobile provides a mobile engagement platform that enables brands to increase awareness, loyalty and ultimately sales. For more information visit www.sitomobile.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our reliance on brand owners and wireless carriers, the possible need for additional capital as well other risks identified in our filings with the SEC. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:
Investor and Media Relations:
Robert Haag
IRTH Communications
[e-mail]
866-976-4784

[MikeDDKing]

Cryoport Announces Pricing of Public Offering of Units and Listing on NASDAQ
July 23, 2015 8:41 PM

LAKE FOREST, Calif., July 23, 2015 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced the pricing of an underwritten public offering of 2,000,000 units at an offering price of $3.25 per unit, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock. The common stock and the warrants are immediately separable, and will trade on The Nasdaq Capital Market under the symbols CYRX, and CYRXW, respectively. The warrants will have a per share exercise price of $3.57, are exercisable immediately and will expire five years from the date of issuance.

Gross proceeds to Cryoport from this offering are approximately $6,500,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cryoport. Cryoport has granted the underwriters a 45-day option to purchase up to an additional 300,000 units to cover over-allotments, if any. The offering is expected to close on July 29, 2015, subject to customary closing conditions.

Aegis Capital Corp. is acting as the sole book-running manager for the offering.

Feltl and Company is acting as a co-manager for the offering.

A registration statement on Form S-1 relating to the common stock and warrants was filed with the Securities and Exchange Commission (SEC) and is now effective. A preliminary prospectus relating to the offering, which forms a part of the effective registration statement, has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov. Copies of the final prospectus relating to the offering, when available, may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: [phone] or email: [e-mail], or from the above-mentioned SEC website.

This press release does not and shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cryoport, Inc.

Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world's largest shipping companies controlling more than 85% of the world's air shipments. For more information, visit www.cryoport.com.

To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.



To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cryoport-announces-pricing-of-public-offering-of-units-and-listing-on-nasdaq-300118227.html

[MikeDDKing]

First Community Financial Partners, Inc. Receives NASDAQ Stock Exchange

JOLIET, Ill., July 15, 2015 (GLOBE NEWSWIRE) -- First Community Financial Partners, Inc. (OTC Pink:FCMP) ("First Community" or the "Company"), the parent company of First Community Financial Bank (the "Bank"), based in Plainfield, Illinois, with six banking offices serving greater Chicagoland, today announced that its common stock has been approved for listing on The NASDAQ Capital Market. The Company expects that the stock will begin trading on NASDAQ on Friday, July 17, 2015, under the newly established ticker symbol "FCFP". The Company’s common stock currently trades over-the-counter under ticker symbol “FCMP”.

Roy Thygesen, Chief Executive Officer, stated: "We believe making the transition to NASDAQ is a logical and prudent step forward for our Company. First Community has been an SEC-reporting corporation for some time now, and our subsidiary Bank’s financial performance has improved markedly in recent years. We have demonstrated earnings growth, and we believe overall financial and operating metrics are trending in the right direction. Reflecting improved financial performance the Company’s stock price, as reported on the OTC Pink Marketplace, appreciated approximately 86% over the past two years. Trading on NASDAQ is expected to increase both retail and institutional investor exposure to the Company, improve trading liquidity for shareholders, and, when appropriate, increase the Company's access to the public and private capital markets to support continued growth of the institution.”

A graph accompanying this release is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/005b38ed-f29d-409e-9a34-dd7dea128fc2

The Company’s focus on generating increased value for shareholders has resulted in a steady increase in the Company’s tangible book value per share from $4.30 at March 31, 2013 to $5.59 at March 31, 2015, which is an increase of 30.0%. Asset quality has improved significantly during this same period, with non-performing assets decreasing $25.9 million or 74.7% since March 31, 2013, to $8.8 million, or 0.91% of total assets, at March 31, 2015.

About First Community Financial Partners, Inc.: First Community Financial Partners, Inc., headquartered in Joliet, Illinois, is a bank holding company whose common stock currently trades on the OTC marketplace (OTC Pink:FCMP). First Community Financial Partners has one bank subsidiary, First Community Financial Bank. First Community Financial Bank, based in Plainfield, Illinois, is a wholly owned banking subsidiary of First Community Financial Partners, with locations in Joliet, Plainfield, Homer Glen, Channahon, Naperville and Burr Ridge, Illinois. The Bank is dedicated to its founding principles by being actively involved in the communities it serves and providing exceptional personal service delivered by experienced local professionals.

Special Note Concerning Forward-Looking Statements

Any statements in this release other than statements of historical facts, including statements about management’s beliefs and expectations, are forward-looking statements and should be evaluated as such. These statements are made on the basis of management’s views and assumptions regarding future events and business performance. Words such as “estimate,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “target,” “project,” “should,” “may,” “will” and similar expressions are intended to identify forward-looking statements. Forward-looking statements (including oral representations) involve risks and uncertainties that may cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. These risks and uncertainties include the ability of First Community and its wholly owned bank subsidiary to realize the synergies from the merger of its non-wholly owned bank subsidiaries, as well as a number of other factors related to the businesses of First Community and its wholly owned bank subsidiary, including: risks associated with First Community’s possible pursuit of acquisitions; economic conditions in First Community’s, and its wholly owned bank subsidiary’s; service areas; system failures; losses of large customers; disruptions in relationships with third party vendors; losses of key management personnel and the inability to attract and retain highly qualified management personnel in the future; the impact of legislation and regulatory changes on the banking industry, including the implementation of the Basel III capital reforms; losses related to cyber-attacks; and liability and compliance costs regarding banking regulations. These and other risks and uncertainties are discussed in more detail in First Community’s filings with the Securities and Exchange Commission, including First Community’s Annual Report on Form 10-K filed on March 13, 2015.

Many of these risks are beyond management’s ability to control or predict. All forward-looking statements attributable to First Community, and its wholly owned bank subsidiary, or persons acting on behalf of each of them are expressly qualified in their entirety by the cautionary statements and risk factors contained in this communication. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. Except as required under the federal securities laws or the rules and regulations of the Securities and Exchange Commission, First Community does not undertake any obligation to update or review any forward-looking information, whether as a result of new information, future events or otherwise.



Contact:

Contact: Glen L. Stiteley, Chief Financial Officer - [phone]

[Mermelstein]

PYDS- split ahead of Nasdaq listing.

New symbol PYDSD. Should be on the Nasdaq within a few weeks.

[Trent Blair]

http://finance.yahoo.com/news/p-dow-jones-indices-announces-211500366.html SEV uplisting to TSX from the venture exchange.

[Trent Blair]

PYDS Announces 15-to-1 Reverse Split of Common Stock http://seekingalpha.com/pr/14155195-payment-data-systems-announces-15-tominus-1-reverse-split-of-common-stock

[steeledge]

ITUS/D approved for nasdaq listing

https://finance.yahoo.com/news/itus-announces-uplisting-nasdaq-200100836.html

(whoops...mike beat me to it)

[MikeDDKing]

ITUS Announces Uplisting to NASDAQ

LOS ANGELES, CA--(Marketwired - July 09, 2015) - ITUS Corporation ("ITUS") (ITUS) today announced that The NASDAQ Stock Market LLC has approved the listing of the Company's stock for trading on The NASDAQ Capital Market. Trading of the Company's securities on The NASDAQ Capital Market will commence effective with the opening of business on Friday, July 10, 2015.

Robert Berman, ITUS's President and CEO, stated, "NASDAQ is the market where shares of the world's most innovative and successful, high-tech companies are traded. With the potentially life saving technologies we are developing at Anixa, our cancer diagnostic subsidiary, and plans for other high-tech initiatives, NASDAQ is exactly where we want to be, and where ITUS belongs."

Shares of the Company's common stock will trade on NASDAQ under the stock symbol "ITUS." Additional information is available in the "Investors" section of the Company's website.

About ITUS Corporation
ITUS funds, develops, acquires, and licenses emerging technologies such as High-Tech, Biotechnology, Life Sciences, and Informatics. The company's wholly owned subsidiary, Anixa Diagnostics, is developing non-invasive, cancer screening tests, and the company and its other subsidiaries have ongoing development and licensing programs involving encrypted communications, advanced materials, and thin-film, flat panel displays. Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2014 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION™
Contact:

Dean Krouch
310-484-5184
[e-mail]

[MikeDDKing]

Aethlon Medical Announces Nasdaq Capital Market Listing Approval

SAN DIEGO, July 8, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's application to list its common stock on the Nasdaq Capital Market has been approved by The NASDAQ Stock Market LLC. Aethlon's common stock is expected to begin trading on the Nasdaq Capital Market at the opening of market hours on Monday, July 13, 2015 under its existing trading symbol, AEMD.

View photo
.Aethlon Hemopurifier.
"Trading on Nasdaq is a pivotal corporate milestone that will help raise the visibility of our therapeutic endeavors and increase the appeal of our shares to mutual funds, pension funds, and other institutional investors that may have previously been restricted from trading our shares," stated Jim Joyce, Chairman and CEO of Aethlon Medical.

About Aethlon Medical, Inc.

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. U.S. clinical progression of Hemopurifier therapy is being advanced under an FDA approved clinical study. We also provide government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. Additional information can be found online at www.AethlonMedical.com or you can connect with us on on Twitter, LinkedIn, Facebook and Google+.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2015, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:

James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
[e-mail]

Jim Frakes
Chief Financial Officer
858.459.7800 x300
[e-mail]

Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc
212-986-6667
[e-mail]

David Zazoff
MDM Worldwide Solutions
646-403-3554
[e-mail]

Photo - http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b



To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medical-announces-nasdaq-capital-market-listing-approval-300110047.html

[TheHound]

Exactly. Very weird. Thanks for your input! If you come across an OTC pink that uplists directly to NASDAQ, please let me know.

[MikeDDKing]

That is weird. It is different because OTC tiers and requirements are different than they once were. A few years ago they would have been listed as OTCBB because they are current on their SEC filings. However, the OTCBB doesn't exist anymore or effectively doesn't exist. They can uplist to NASDAQ any time now. They just need to get the stock price to the appropriate level. They have already filed their 8-A12B which always happens before uplist.

[TheHound]

Thanks. I'm very long on CTIX. Also hold a sizable trade position. They are OTC pink. Current and fully reporting. Apparently when the recent teir changes occurred on the OTC, they opted to forgo the rate increase to stay on the QB, downlisted to the pinks and now have an application into NASDAQ. The move doesn't make much sense to me. Could they be the first company to pull it off?

[MikeDDKing]

I don't think I have ever seen a direct uplist from pink sheets to Nasdaq. A company needs to become an SEC filer before uplisting. So, from a practical perspective that means they are going to be on the OTC for at least a little bit.

[TheHound]

Hi all. Do you know of any companies that have successfully up listed directly to Nasdaq from the pink sheets? I see you have a few listed above but the couple I've looked into was actually trading on other platforms when they finally uplisted. SGYP for example... Thanks in advance. Appreciate your time.

Hound

[MikeDDKing]

Ener-Core Announces Reverse Stock Split in Preparation for Proposed Uplisting to a National Securities Exchange

IRVINE, Calif.--(BUSINESS WIRE)--

Ener-Core, Inc. (“Ener-Core” or “the company”) (ENCR), the world’s only provider of commercialized Power Oxidation technology and equipment that generates clean power from low-quality and waste gases from a wide variety of industries, today announced that it will effect a 1-for-50 reverse stock split of the company’s authorized, issued and outstanding common stock (the “Reverse Stock Split”) in preparation for its proposed listing of its common stock on a national securities exchange (the “Proposed Listing”). Both the Reverse Stock Split and the Proposed Listing are contractual obligations of Ener-Core pursuant to a Securities Purchase Agreement, dated April 22, 2015.

“We are pleased to complete the reverse split and proceed with our preparations to list on a national securities exchange,” said Alain Castro, Chief Executive Officer of Ener-Core. “We view these actions as important steps in advancing Ener-Core’s corporate development. We believe the proposed uplisting to a national exchange will help to enhance our visibility and may provide greater liquidity to our stock. In fulfilling the reverse split commitment under our recent Securities Purchase Agreement, we also reflect our appreciation for the continued support of our stockholders who participated in that transaction.“

The Reverse Stock Split became effective with the Financial Industry Regulatory Authority (“FINRA”) as of the close of business on July 7, 2015 and will become effective with the Secretary of State of the State of Nevada as of 12:01 a.m. Eastern Time on July 8, 2015. The company’s common stock will begin trading on a split-adjusted basis at the open of business on July 8, 2015.

At the effective time of the 1-for-50 Reverse Stock Split, every 50 shares of issued and outstanding common stock will be converted into 1 share of issued and outstanding common stock, and the authorized shares of common stock will be reduced from 200,000,000 to 4,000,000 shares. All fractional shares of common stock will be rounded up to the nearest whole share. Immediately after the Reverse Stock Split becomes effective, Ener-Core will have approximately 2,463,919 shares of common stock outstanding.

Ener-Core’s common stock will trade under the ticker symbol “ENCRD” for a period of 20 business days after the Reverse Stock Split has been effected in the marketplace, and the common stock will also trade under a new CUSIP number of 29272A 206. Before any listing of the common stock on a national securities exchange can occur, Ener-Core will need to prepare, file and receive approval of an application for such listing after the Reverse Stock Split is completed. The company’s Proposed Listing is subject to review by such exchange and dependent upon the company satisfying all relevant quantitative and qualitative listing criteria of such exchange. As such, there can be no assurance that such exchange will approve the company’s application for listing.

Stockholders of record are not required to send in their current stock certificates or evidence of book-entry or other electronic positions for exchange. Following the effectiveness of the Reverse Stock Split, each stock certificate and book-entry or other electronic position representing issued and outstanding shares of the Ener-Core’s common stock will be automatically adjusted. Those stockholders holding common stock in “street name” will receive instructions from their brokers if they need to take any action in connection with the Reverse Stock Split. Stockholders should direct any questions concerning the Reverse Stock Split to their broker or Ener-Core’s transfer agent and register, VStock Transfer, LLC. VStock Transfer can be contacted at [phone].

For additional information about the Reverse Stock Split and related administrative matters, see Ener-Core’s Current Report on Form 8-K filed July 7, 2015, available at www.sec.gov.

About Ener-Core

Irvine, California-based Ener-Core, Inc. (ENCR) designs, manufactures and has commercially deployed unique systems that generate base load, clean power from polluting waste gases including methane. Ener-Core’s patented Power Oxidizer is the only solution of its kind that turns one of the most potent pollution sources into a profitable, “always on” source of clean energy. Ener-Core’s technology offers a revolutionary alternative to the flaring (burning) of gaseous pollution while generating operating efficiencies and ensuring compliance with costly environmental regulations.

Ener-Core offers a variety of platforms including the 250kW Ener-Core Powerstation EC250 (“EC250”), the Ener-Core Power Oxidizer 333 KW Powerstation (“EC333”) and the larger counterpart, the 2MW Ener-Core Powerstation KG2-3GEF/PO.

Cautionary Statement Regarding Forward-Looking Statements

Forward-looking statements contained in this press release are made under the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995. Information provided by Ener-Core, such as online or printed documents, publications or information available via its website may contain forward-looking statements that involve risks, uncertainties, assumptions, and other factors, which, if they do not materialize or prove correct, could cause its results to differ materially from historical results, or those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “planned,” “expects,” “believes,” “strategy,” “opportunity,” “anticipates,” and similar words. These statements may include, among others, plans, strategies, and objectives of management for future operations; any statements regarding proposed new products, services, or developments; any statements regarding future economic conditions or performance; statements of belief; and any statements of assumptions underlying any of the foregoing. The information contained in this release is as of the date of this press release. Except as otherwise expressly referenced herein, Ener-Core assumes no obligation to update forward-looking statements.


View source version on businesswire.com: http://www.businesswire.com/news/home/20150707006604/en/

Contact:
Investor Relations:
Dian Griesel Int’l.
Enrique Briz, [phone]
or
Cheryl Schneider, [phone]

[MikeDDKing]

CUBN uplists...

Commerce Union Bancshares, Inc. Approved to Trade on Nasdaq

BRENTWOOD, Tenn.--(BUSINESS WIRE)--

Commerce Union Bancshares, Inc. announced today that received approval for its stock to trade on The Nasdaq Stock Market. Commerce Union’s stock will begin trading on The Nasdaq Stock Market effective July 7, 2015 under the stock symbol CUBN.

“We are pleased to announce that Commerce Union Bancshares’ stock will begin trading on The Nasdaq Stock Market effective July 7th,” stated William R. DeBerry, Chairman and Chief Executive Officer. “We believe the Nasdaq listing will provide increased visibility for our company with investors and increased marketability of our shares for our stockholders.”

Commenting on the listing, DeVan Ard, President of Commerce Union stated, “The Nasdaq listing represents an important milestone in our combination of Commerce Union and Reliant banks. The merger strengthened our capital base, increased our lending limits, expanded the reach of our combined banks and improved our operating synergies. We believe the Nasdaq listing highlights our continued progress to build long-term shareholder value by combining our resources.”

About Commerce Union Bancshares, Inc. and Commerce Union Bank

Commerce Union Bank is a full-service commercial bank that offers a variety of deposit, lending and mortgage products and services to business and consumer customers located in Davidson, Robertson, Rutherford, Sumner and Williamson Counties, Tennessee. Commerce Union Bancshares’ stock is traded on The Nasdaq Stock Market under the symbol “CUBN.” For additional information, locations and hours of operation, please visit www.commerceunionbank.com.

Forward-Looking Statements

Statements in this press release relating to Commerce Union Bancshares’ plans, objectives, expectations or future performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “should,” “anticipate,” “estimate,” “expect,” “intend,” “objective,” “possible,” “seek,” “plan,” “strive” or similar words, or negatives of these words, identify forward-looking statements. These forward-looking statements are based on management’s current expectations. The Company’s actual results in future periods may differ materially from those indicated by forward-looking statements due to various risks and uncertainties. These risks and uncertainties are described in greater detail under “Risk Factors” in the Company’s most recent annual report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date of the release and the Company does not assume any responsibility to update these statements.


View source version on businesswire.com: http://www.businesswire.com/news/home/20150706005554/en/

Contact:
Commerce Union Bank
DeVan Ard, 615-221-2020
President and Chief Executive Officer
or
Commerce Union Bancshares, Inc.
Ron DeBerry, 615-433-7200
Chairman and Chief Executive Officer

[MikeDDKing]

Good updates....Thanks.

[Trent Blair]

http://biz.yahoo.com/e/150702/pyds8-k.html PYDS approved their reverse split. They now meet all requirements to uplist to the Nasdaq once the reverse split happens.

[Trent Blair]

$CURM Reverse split and uplisting to NASDAQ. http://t.co/qNGCFGapHC

[MikeDDKing]

VSUL to uplist to Nasdaq.

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10780845-1120-5755&type=sect&TabIndex=2&companyid=60426&ppu=%252fdefault.aspx%253fcik%253d1074828

[MikeDDKing]

ITUS Announces Reverse Stock Split With the Intention to List Shares on NASDAQ

LOS ANGELES, CA--(Marketwired - June 25, 2015) - ITUS Corporation ("ITUS") (ITUS), today announced that effective at 9:00 a.m. Eastern Standard Time on Friday, June 26, 2015, the company will implement a 1 for 25 reverse stock split of its common shares. The company's common stock will begin trading on a post-reverse stock split basis on the OTCQB under the temporary symbol "ITUSD" effective with the open of business on June 26, 2015. The company's shareholders approved implementation of a reverse stock split on August 8, 2014, and the company's board of directors has determined to take such action to help the company become eligible for listing on The NASDAQ Stock Market.

Robert Berman, ITUS's President and CEO, stated, "The excessively large number of outstanding ITUS shares has been an ongoing concern raised by investors and others in the financial community. With the announcement of our new business direction and the launch of exciting initiatives such as Anixa, our cancer diagnostics subsidiary, the timing is right to clean up the capital structure of the company as we complete our transformation and position the company for long term success."

As a result of the reverse stock split, every 25 shares of ITUS's issued and outstanding shares of common stock will be automatically converted into 1 share of common stock. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share. Additionally, as a result of the reverse stock split the number of shares of ITUS's common stock and preferred stock authorized under our Certificate of Incorporation, as amended, will be decreased by the same proportion as the outstanding shares of common stock.

The reverse stock split will reduce the number of ITUS's issued and outstanding common stock from approximately 219 million shares, pre-reverse stock split, to approximately 8.8 million shares, post-reverse stock split. In most instances, the only way to obtain new ITUS share certificates will be to physically exchange old share certificates. To facilitate a smooth transition, we recommend that shareholders first obtain possession of their physical stock certificates. If necessary, shareholders should request such certificates from their brokers, if they have not already done so. Shareholders will receive detailed instructions for obtaining new share certificates from the company's transfer agent within the next 6 weeks, and instructions will also be made available in the "Investor" section of the ITUS website. A new CUSIP number of 45069V203 will replace the pre-reverse split CUSIP number of 45069V104 to distinguish between the company's pre- and post-reverse split shares of common stock.

About ITUS Corporation
ITUS funds, develops, acquires, and licenses emerging technologies such as High-Tech, Biotechnology. Life Sciences, and Informatics. The company has ongoing licensing programs involving encrypted communications, and advanced materials, and an ongoing development program to create highly efficient, flat panel displays, utilizing a proprietary technology for carbon Nanotubes and phosphor luminescence. Additional information is available at www.ITUScorp.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2014 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION™
Contact:

Ron Tenio
310-484-5197
[e-mail]

Dean Krouch
310-484-5184
[e-mail]

[MikeDDKing]

PIRS to uplist

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10775665-943-4958&type=sect&TabIndex=2&companyid=913859&ppu=%252fdefault.aspx%253fcik%253d1583648

[steeledge]

CTEI-->CETX NASDAQ 6/25

https://finance.yahoo.com/news/cemtrex-inc-announces-uplisting-nasdaq-125500179.html

[steeledge]

DHXM NAS Global mkt approval for listing (also on Toronto)

https://finance.yahoo.com/news/dhx-media-commence-trading-nasdaq-185800081.html

[MikeDDKing]

CTEI files to uplist to Nasdaq.

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10771247-787-6125&type=sect&TabIndex=2&companyid=778521&ppu=%252fdefault.aspx%253fcik%253d1435064

[MikeDDKing]

Orion Energy Systems to Move to NASDAQ Capital Market

Orion Energy Systems, Inc. (NYSE MKT:OESX), June 3, 2015 - a leading designer and manufacturer of high-performance, energy-efficient retrofit lighting platforms, today announced it will voluntarily transfer its stock exchange listing from the NYSE MKT to the NASDAQ Capital Market effective June 15, 2015. The last day of trading on the NYSE MKT is expected to be June 12, 2015.

Orion’s stock will continue to trade under the ticker symbol OESX.

“We believe that listing on the NASDAQ Capital Market supports the upward direction of our company and offers the best platform of services for investing in Orion,” said Orion's Chief Executive Officer, John Scribante.

About Orion Energy Systems

Orion is leading the transformation of commercial and industrial buildings with state-of-the-art energy efficient lighting systems and retrofit lighting solutions. Orion manufactures and markets a cutting edge portfolio of products encompassing LED Solid-State Lighting and high intensity fluorescent lighting. Many of Orion's 100+ granted patents and pending patent applications relate to lighting systems that provide exceptional optical and thermal performance, which drive financial, environmental, and work-space benefits for a wide variety of customers in the retrofit markets.


View source version on businesswire.com: http://www.businesswire.com/news/home/20150603006635/en/

Contact:
Investor Relations:
Orion Energy Systems, Inc.
Scott Jensen, [phone]
Chief Financial Officer
or
Media Relations:
Orion Energy Systems, Inc.
Erica St. Angel, [phone]
SVP Marketing

[MikeDDKing]

BPMX to uplist to NYSE MKT.

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10734204-903-6512&type=sect&TabIndex=2&companyid=840082&ppu=%252fdefault.aspx%253fcik%253d1504167

[MikeDDKing]

Milestone Scientific Announces Approval for Listing on the NYSE MKT

LIVINGSTON, NJ--(Marketwired - May 28, 2015) - Milestone Scientific Inc. (MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its shares of common stock have been approved for listing on the NYSE MKT, subject to continued satisfaction of listing requirements. Trading on the NYSE MKT is expected to commence on June 1, 2015. The Company will continue to trade under the symbol "MLSS."

"Trading on the NYSE MKT is an important development for the Company and reflects our continued progress as we move forward with our medical instruments. These instruments represent a leap forward in drug delivery technology, which remained relatively unchanged since the invention of the hypodermic syringe in the 1800s. Our computer-controlled instruments are designed to provide safe, controlled and painless injections, as well as help reduce costs and malpractice risk for healthcare professionals," commented Leonard Osser, CEO of Milestone Scientific. "Listing on the NYSE MKT should provide the Company increased exposure within the investment community and improved liquidity."

NYSE MKT is a fully integrated trading venue within the NYSE community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE community.

"We welcome Milestone Scientific to the NYSE MKT family of listed companies," said Garvis Toler, Global Head of Capital Markets, NYSE. "Milestone will be joining other well-known medical device companies taking advantage of the NYSE's advanced and innovative market model to offer a premier value for listing and trading their stocks."

About Milestone Scientific

Milestone Scientific Inc. (MLSS) is a medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:

David Waldman or Klea Theoharis
Crescendo Communications, LLC
Email: [e-mail]
Tel: [phone]

[MikeDDKing]

OncoSec Medical Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

SAN DIEGO, May 14, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Secretary of State of Nevada on May 18, 2015 and the company's common stock will begin trading on a split-adjusted basis upon Financial Industry Regulatory Authority (FINRA) approval.

"This reverse stock split represents a critical milestone for OncoSec as we intend to uplist to a national securities exchange to attract a broader, more diverse shareholder base," said Punit Dhillon, CEO and President of OncoSec. "We believe that this is the next logical step for our company as we continue to enhance our intratumoral immunotherapy technology and advance our clinical pipeline. With the support of our shareholders, we look forward to validating our ImmunoPulse™ technology in clinical and preclinical studies, generating more value for our investors, and securing our place in this long-awaited revolution in cancer treatment."

At the effective time of the 1-for-20 reverse stock split, every 20 shares of issued and outstanding common stock will be converted into 1 share of issued and outstanding common stock, and the authorized shares of common stock will be reduced from 3,200,000,000 to 160,000,000 shares. All fractional shares of common stock will be rounded up to the nearest whole share. Immediately after the reverse stock split becomes effective, the company will have approximately 12,350,132 shares of common stock outstanding.

OncoSec's common stock will trade under the ticker symbol "ONCSD" for a period of 20 business days after the reverse stock split has been effected in the marketplace, and the common stock will also trade under a new CUSIP number of 68234L207. Before any listing of the common stock on the NASDAQ Capital Market could occur, NASDAQ will need to approve the company's application for listing after the reverse stock split is completed.

Shareholders of record are not required to send in their current stock certificates or evidence of book-entry or other electronic positions for exchange. Following the effectiveness of the reverse stock split, each stock certificate and book-entry or other electronic position representing issued and outstanding shares of the company's common stock will be automatically adjusted. Those shareholders holding common stock in "street name" will receive instructions from their brokers if they need to take any action in connection with the reverse stock split.

If a shareholder holding a paper stock certificate would like to send the certificate to the company's transfer agent for exchange, then the transfer agent will issue a new stock certificate reflecting the terms of the reverse stock split to such requesting shareholder. In that event, stock certificates could be mailed to the company's transfer agent at the following address:

Nevada Agency and Transfer Company
50 West Liberty Street, Suite 880
Reno, Nevada 89501

All of the company's options, warrants, and other convertible securities that are outstanding immediately before the reverse stock split will also be adjusted by dividing the number of shares of common stock into which the options, warrants, and other convertible securities are exercisable or convertible by 20 and multiplying the exercise or conversion price thereof by 20, all in accordance with the terms of the plans, agreements, or arrangements governing such options, warrants, and other convertible securities.

For additional insight into the company's reverse stock split and future plans, please visit the "CEO's Perspective" on OncoSec's website: http://oncosec.com/ceo-perspective-reverse-split-and-uplisting.

About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse™ for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse™ in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements," including statements regarding, among other things, the effectiveness of the reverse stock split, including FINRA's approval thereof, the company's plans to list its common stock on the NASDAQ Capital Market, or any other national securities exchange, and the impact the reverse stock split or any such listing may have on the company's business, prospects and/or stock price. Forward-looking statements are based on management's current views, assumptions and preliminary expectations and are subject to risks and uncertainties, which may cause actual results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include the timing and decisions of regulators regarding proposed company actions, which are largely out of our direct control, our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

[MikeDDKing]

Apollo Medical Holdings Announces reverse stock split and nasdaq listing submission

GLENDALE, Calif., April 24, 2015 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed") (AMEH), an integrated patient-centered, physician-driven healthcare delivery company, today announced that it has effected a one-for-ten (1-for-10) reverse stock split of its common stock. Beginning with the opening of trading on April 27, 2015, the Company's common stock will trade on a split-adjusted basis. The Company also announced that it has submitted an initial listing application to the NASDAQ Stock Market to have its common stock approved for listing on the NASDAQ Capital Market.

The Board of Directors approved the reverse stock split on April 17, 2015, pursuant to authorization by shareholders at the Company's annual meeting held on September 30, 2014. The Board approved the stock split to support the NASDAQ Capital Market listing application. The Company cannot assure that the listing will be approved.

Following the reverse stock split, each ten shares of the Company's issued and outstanding common stock will be automatically converted into one issued and outstanding share of the Company's common stock. The reverse stock split will affect all issued and outstanding shares of the Company's common stock, as well as common stock underlying stock options, warrants, other common stock-based equity grants and any other of the Company's securities converted into or exchangeable for shares of the Company's common stock, outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of common stock will receive a cash payment in lieu of such fractional share. The reverse stock split will not affect any stockholder's ownership percentage of the Company's common stock, except to the limited extent that the reverse stock split would result in any fractional shares, which will be cashed out.

The reverse stock split will reduce the number of shares of the Company's issued and outstanding common stock from approximately 48.6 million to approximately 4.86 million. The reverse stock split does not have any effect on the Company's authorized capital stock.

The Company's trading symbol of "AMEH" will not change as a result of the reverse stock split, although it is expected that the letter "D" will be appended to the Company's ticker for approximately 20 trading days following the effective date to indicate the completion of the reverse stock split. In addition, the common stock will trade under a new CUSIP number, 03763A207.

Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the reverse stock split as of the effective date. Stockholders with existing stock certificates who have questions may call the Company's transfer agent, OTC Stock Transfer, at 801-272-7272. Stockholders with fractional shares will be cashed out directly by the Company without further action required by these stockholders.

Related Quotes
AMEH
0.45
-13.43%
Apollo Medical Holdings, Inc.? Watchlist
0.45-0.07(13.43%)
OTC MarketsFri, Apr 24, 2015 2:51 PM EDT

APOLLO MEDICAL HOLDINGS, INC. Financials EDGAR Online Financials 14 days ago
APOLLO MEDICAL HOLDINGS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to EDGAR Online 17 days ago
More
About Apollo Medical Holdings, Inc.

Headquartered in Glendale, California, ApolloMed is a leading integrated patient-centered, physician-centric healthcare delivery company committed to providing exceptional multi-disciplinary care in the communities it serves. ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated healthcare delivery platform comprised of six affiliated and complementary physician groups: ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group (Independent Physician Association), AKM Medical Group (IPA), ApolloMed Care Clinics and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care. For more information, please visit www.apollomed.net

Forward Looking Statements

This press release may contain forward-looking statements, including information about management's view of future expectations, plans and prospects for Apollo Medical Holdings, Inc. ("the Company"). In particular, when used in the preceding discussion, the words "predicts," "believes," "expects," "intends," "seeks," "estimates," "plans," "anticipates," and similar conditional expressions or future or conditional verbs such as "will," "may," "might," "should," "would" and "could" are intended to identify forward-looking statements. In addition, our representatives may from time to time make oral forward-looking statements. Any such statements, other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based on the current expectations and certain assumptions of the Company's management. Such statements are, therefore, subject to a variety of known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company, which could cause the actual results, performance or achievements of the Company, its subsidiaries and concepts to be materially different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company's actual results, performance or achievements may vary materially from those described in the relevant forward-looking statement as being expected, anticipated, intended, planned, believed, sought, estimated or projected. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included herein are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company has submitted an initial listing application to the Nasdaq Stock Market to have its common stock approved for listing on the Nasdaq Capital Market. At present, the Company does not meet all of the initial listing requirements of the Nasdaq Capital Market and therefore the Company cannot assure that the listing will be approved. Finally, the Company undertakes no obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under Item 1A. "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended January 31, 2014 and in any of the Company's other subsequent Securities and Exchange Commission filings.

FOR ADDITIONAL INFORMATION
RedChip Companies
Michael Sullivan
800-733-2447 Ext. 115 or via email at [e-mail]

[MikeDDKing]

Vivakor to Up-List to Major US Exchange in 2015

IRVINE, CA--(Marketwired - April 09, 2015) - Vivakor, Inc. (OTC PINK: VIVK) announced the company's intention to up-list to one of the major exchanges in 2015. The company is targeting either the NASDAQ or NYSE MKT LLC, formerly known as the American Stock Exchange (AMEX).

Matt Nicosia, Chairman and CEO expressed, "as we drive toward our major exchange up-list, the Growth Capital Expo in Las Vegas provides Vivakor a great platform with significant visibility from institutional investors across the globe. We are pleased to have been selected to speak and share our story. Several organizations have been targeted to assist us in the up-list and the upcoming Expo enables us to look at a few more potential sponsors.

We have executed on our goals and objectives since 2013 and our financials are indicative of our achievements in building an investment quality balance sheet. This has prepared us for strong institutional sponsorship as we move toward the up-list. We maintain our fiscal prudence as we decrease our liabilities, while driving asset accumulation and preserving capital as we move toward the up-list we've discussed. There are very specific criteria requirements that Vivakor must observe in order to effectively move to a fruitful up-list and our selection of the right partner(s) is vital to that success. This up-list further empowers Vivakor to maintain its proven, practical business model for such purposes as asset accumulation and capital application for projects, technologies and value based assets to further grow the company."

Vivakor is conducting a meet and greet on Monday evening, April 13th in the Sake Suite inside the Nobu Hotel at Caesars Palace starting at 7:00 PM. Interested parties are invited to come and meet with Vivakor Executives.

ABOUT VIVAKOR, INC.

Vivakor, Inc. (VIVK) is an Asset Acquisition company that develops and acquires resources that generate revenue currently or in the near term. The Company acquires technologies and assets primarily in the field of Natural Resources. Vivakor owns and operates multiple mineral assets that have great value and create a cash flow and a long term revenue stream for the Company. Additionally, the Company has effectively acquired positions in other Green Energy companies. The general business model is to acquire cash-flowing or near term cash-flowing mineral and or technology assets that have unique characteristics with an identified need or a substantial market opportunity. For more information please visit www.vivakor.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
Contact:

Vivakor Investor Relations
[phone]
[e-mail]

[MikeDDKing]

The ONE Group Hospitality To List on NASDAQ
Company shares expected to begin trading on the NASDAQ Capital Market on May 8th

The ONE Group Hospitality, Inc. (“The ONE Group”) (STKS), today announced that its common stock has been approved for listing on the NASDAQ Capital Market (NASDAQ) and is expected to begin trading on NASDAQ under the symbol “STKS” beginning May 8, 2015. The Company's common stock will continue to trade on the OTCQB until the market close on May 7, 2015.

“We are excited to announce the completion of this important next step in the evolution of our company and extension of our growth strategy,” shared Jonathan Segal, CEO of The ONE Group. “Uplisting to NASDAQ has always been part of our plan and we believe further strengthens our credibility in the marketplace, and is a testament to the hard work of our employees and leadership team. Looking forward, we believe that this move will help us to draw interest from attractive partners as well as new shareholders.”

About The ONE Group

The ONE Group is a global hospitality company that develops and operates upscale, high-energy restaurants and lounges and provides hospitality management services for hotels, casinos and other high-end venues both nationally and internationally. The ONE Group’s primary restaurant brand is STK, a modern twist on the American steakhouse concept with locations in major metropolitan cities throughout the U.S. and in London. STK Rebel, a more accessibly priced STK with a broader menu, is an extension of the STK brand. The ONE Group’s food and beverage hospitality services business, ONE Hospitality, provides the development, management and operations for premier restaurants and turn-key food and beverage services within high-end hotels and casinos. Additional information about The ONE Group can be found at www.togrp.com.

Cautionary Statement on Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements, including but not limited to, (1) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, our ability to open new restaurants and food and beverage locations in current and additional markets, grow and manage growth profitably, maintain relationships with suppliers and obtain adequate supply of products and retain our key employees; (2) factors beyond our control that affect the number and timing of new restaurant openings, including weather conditions and factors under the control of landlords, contractors and regulatory and/or licensing authorities; (3) changes in applicable laws or regulations; (4) the possibility that the ONE Group may be adversely affected by other economic, business, and/or competitive factors; and (5) other risks and uncertainties indicated from time to time in our filings with the SEC, including our Annual Report on Form 10-K/A filed on April 1, 2015.

Investors are referred to the most recent reports filed with the SEC by The ONE Group Hospitality, Inc. Investors are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.


Contact:
Media:
Sloane & Company
Dan Zacchei or Kate Traynor, 212-486-9500
or
Investors:
ICR
Don Duffy or Sheryl Freeman, 203-682-8200

[MikeDDKing]

CTIX to uplist to Nasdaq....

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10646174-939-4593&type=sect&TabIndex=2&companyid=717529&ppu=%252fdefault.aspx%253fcik%253d1355250

[Hole shot King]

MyECheck Re-Files Form 10 for Registration of Securities With SEC

FOLSOM, CA--(Marketwired - Apr 8, 2015) - MyECheck, Inc. (OTC PINK: $MYEC), the leader in electronic check solutions for internet and mobile payments, announced today that it has filed a Form 10 with the Securities Exchange Commission, also known as General Form For Registration of Securities.
The purpose of the Form 10 filing is to register its class of common stock with the SEC, to become fully reporting with the SEC, improving company transparency, and to qualify for a more senior stock exchange.
The Form 10 Registration statement contains audited financial statements through 2014, and all pertinent information related to the business of the MyECheck.
The registration becomes effective after SEC acceptance. MyECheck previously filed a Form 10 with the SEC last October, however withdrew the application due to the fact the audited financial statements needed to cover all of 2014.

http://www.marketwired.com/press-release/myecheck-re-files-form-10-for-registration-of-securities-with-sec-otc-pink-myec-2007743.htm

[Hole shot King]

$MYEC share structure Reduction


## source: otcmarkets.com

Market Value: $69,881,611 a/o Apr 21, 2015
Shares Outstanding: 3,882,311,732 a/o Apr 21, 2015
Float: 1,889,730,863 a/o Apr 22, 2015
Authorized Shares: 4,900,000,000 a/o Dec 31, 2014
Par Value: 0.0001

http://www.otcmarkets.com/stock/MYEC/profile


Float was 2,155730,863 Apr 21 2015

[MikeDDKing]

Signature Group Holdings to List on The NASDAQ Stock Market LLC; Ticker Symbol to Change to “RELY” to Reflect Pending Corporate Name Change to Real Industry, Inc.

Signature Group Holdings, Inc. (SGRH) (“Signature” or the “Company”) today announced that it has received approval to list its common shares on the Nasdaq Global Select Market.

The common shares are expected to commence trading on the Nasdaq Global Select Market on Tuesday, April 21, 2015, under the symbol “RELY”. Prior to its move to The NASDAQ Stock Market LLC (the “NASDAQ”), the Company will continue to trade on the OTC Markets under the symbol SGRH.

As previously announced, the Company intends to change its corporate name to Real Industry, Inc., to better reflect the Company’s strategy of engaging in strategic business acquisitions focused on sectors that include transportation, food, water and energy. The corporate name change is subject to stockholder approval.

Craig T. Bouchard, Chairman and CEO of Signature, stated, “We are delighted to make the shift over to the NASDAQ. This transition marks an important milestone for our Company. We believe that trading on NASDAQ will lead to increased and improved liquidity, an expansion in our shareholder base and, ultimately, to increased shareholder value.”

Conference Call Reminder

Related Quotes
SGRH
7.24
0.00%
Signature Group Holdings, Inc.? Watchlist
7.240.00(0.00%)
OTC Markets10:35 AM EDT

SIGNATURE GROUP HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online 4 days ago
SIGNATURE GROUP HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online 15 days ago
More
As previously announced, the Company will hold a conference call for investors this afternoon (Thursday, April 16, 2015), at 4:30 p.m. ET, which will include prepared remarks by management to provide an update on the Company, including its Real Alloy business, strategy and objectives. This will be followed by a Q&A session.

Call Participants

Craig Bouchard, Chairman of the Board and Chief Executive Officer of Signature
Kyle Ross, Executive Vice President and Chief Financial Officer of Signature
John Miller, newly-named Executive Vice President of Operations of Signature
Terry Hogan, President of Real Alloy
Mike Hobey, Chief Financial Officer of Real Alloy
Dial-in Numbers

[phone] (Toll-free U.S. & Canada)
[phone] (International)

Webcast Access

Participants may also access the live call via webcast at http://signaturegroupholdings.equisolvewebcast.com/inv-update. The webcast will be archived and accessible for approximately 30 days.

About Signature Group Holdings, Inc.

Signature is a North America-based holding company seeking to invest its capital in large, well-managed and consistently profitable businesses concentrated primarily in the United States industrial and commercial marketplace. Signature has significant capital resources, and federal net operating loss tax carryforwards of more than $900 million. For more information about Signature, visit its corporate website at www.signaturegroupholdings.com.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking statements, which are based on our current expectations, estimates, and projections about Signature’s and its subsidiaries’ businesses and prospects, as well as management’s beliefs, and certain assumptions made by management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “should,” “will” and variations of these words are intended to identify forward-looking statements. Such statements speak only as of the date hereof and are subject to change. Signature undertakes no obligation to revise or update publicly any forward-looking statements for any reason. These statements include, but are not limited to, statements about Signature’s and its subsidiaries’ rebranding efforts, expansion and business strategies; anticipated growth opportunities; the amount of capital-raising necessary to achieve those strategies; utilization of federal net operating loss tax carryforwards; listing on a national securities exchange; as well as future performance, growth, operating results, financial condition and prospects. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Accordingly, actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Important factors that may cause such a difference include, but are not limited to Signature’s ability to successfully identify, consummate and integrate acquisitions and/or other businesses; Signature’s ability to successfully rebrand itself with a new name; changes in business or other market conditions; the difficulty of keeping expense growth at modest levels while increasing revenues; Signature’s ability to successfully defend against current and new litigation and indemnification matters, as well as demands by investment banks for defense, indemnity, and contribution claims; Signature’s ability to access and realize value from its federal net operating loss tax carryforwards; Signature’s ability to identify and recruit management and directors; Signature’s ability to satisfy and maintain the listing requirements of the NASDAQ; and other risks detailed from time to time in Signature’s Securities and Exchange Commission filings, including but not limited to the most recently filed Annual Report on Form 10-K and subsequent reports filed on Forms 10-Q and 8-K.

Rule 14a-12 Legend

On April 10, 2015, Signature filed a preliminary proxy statement in connection with its 2015 annual meeting of stockholders. Prior to the annual meeting, Signature will furnish a definitive proxy statement to its stockholders, together with a proxy card. Signature stockholders are strongly advised to read Signature’s proxy statement as it contains important information. Stockholders may obtain Signature’s preliminary proxy statement, any amendments or supplements to the proxy statement and other documents filed by Signature with the Securities and Exchange Commission for free at the Internet website maintained by the Securities and Exchange Commission at www.sec.gov. Copies of the definitive proxy statement and any amendments and supplements to the definitive proxy statement will also be available for free at Signature’s Internet website at www.signaturegroupholdings.com or by writing to Signature Group Holdings, Inc., 15301 Ventura Boulevard Suite 400, Sherman Oaks, California 91403. In addition, copies of Signature’s proxy materials may be requested by contacting our proxy solicitor, Morrow & Co., LLC at 800-662-5200 toll-free. Detailed information regarding the names, affiliations and interests of individuals who are participants in the solicitation of proxies of Signature’s stockholders is available in Signature’s preliminary proxy statement filed with the Securities and Exchange Commission on April 10, 2015.


Contact:
Signature Group Holdings, Inc.
Jeff Crusinberry, 805-435-1255
Senior Vice President and Treasurer
[e-mail]

[Mermelstein]

PYDS- applies for Nasdaq listing. Should be a shoo-in.

[MikeDDKing]

NVIV uplisting - http://finance.yahoo.com/news/invivo-therapeutics-announces-uplisting-nasdaq-120000359.html

[MikeDDKing]

Cemtrex (OTC: CTEI) Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ Exchange

FARMINGDALE, N.Y., April 14, 2015 /PRNewswire/ -- Cemtrex Inc. (www.cemtrex.com) announced today that in preparation for its planned uplisting to the NASDAQ CM Exchange, it is effecting a 1 for 6 reverse stock split of its common stock, to be effective for trading purposes as of the commencement of trading on April 15th, 2015. As of this date, every six (6) shares of issued and outstanding common stock will be converted into one (1) share of common stock.

Photo - http://photos.prnewswire.com/prnh/20150413/198208LOGO

As of the market open on April 15th, the common stock will be trading under a new CUSIP number (15130G303), although the Company's ticker symbol, CTEI, will remain unchanged. However, the company's shares of common stock will trade on the OTCQC Marketplace under symbol, "CTEID", with the "D" added for the next 20 trading days to signify the stock split.

"Many of our shareholders and investors have supported our interest in moving Cemtrex to the NASDAQ Capital Markets exchange," said Saagar Govil, Chairman and Chief Executive Officer of Cemtrex. He continued, "We view this reverse split as one of the last remaining steps in meeting the requirements to be on the exchange and are working to get this important company milestone completed swiftly. Uplisting to a major exchange like NASDAQ will better enable us to attract a broader range of institutional investors and increase share liquidity."

As a result of the Reverse Split, the total issued and outstanding common shares will be reduced from approximately 40.7 million shares to approximately 6.8 million, subject to adjustment for fractional shares. No fractional shares will be issued in connection with the reverse stock split. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.

Stockholders who hold their shares in brokerage accounts or "street name" will have their shares automatically adjusted to reflect the reverse stock split. Holders of share certificates will receive instructions from the company's transfer agent, First American Stock Transfer, Inc. with specific instructions regarding the exchange of shares. Stockholders should direct any questions concerning the Reverse Split to their broker or the Company's transfer agent, First American Stock Transfer, [phone].

About Cemtrex, Inc.
Cemtrex, Inc. (OTC: CTEI) is a diversified technology company that provides a wide array of solutions to meet today's industrial challenges. Cemtrex, through its wholly owned subsidiaries provides electronic manufacturing services of custom engineered printed circuit board assemblies, emission monitors & instruments for industrial processes, and environmental control & air filtration systems for industries & utilities.

www.cemtrex.com

Safe Harbor Statement
This press release contains forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date.

For further information, please contact:

Investor Relations
Cemtrex, Inc.
Phone: [phone]
Email

[MikeDDKing]

Corbus Pharmaceuticals Announces Uplisting to The NASDAQ Capital Market

Company Stock to Commence Trading on NASDAQ on April 16, 2015, Under

NORWOOD, MA--(Marketwired - Apr 13, 2015) - Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab,™ for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that the NASDAQ Stock Market LLC has approved the Company's application to have its common stock listed on The NASDAQ Capital Market (NASDAQ). The stock will commence trading on The NASDAQ Capital Market on April 16, 2015, under its existing ticker symbol CRBP.

"Becoming a NASDAQ-listed company marks an important milestone for Corbus and reflects the hard work and dedication of our management team to build a strong, innovative, clinical stage biotech company," commented Sean Moran, CPA, MBA, Chief Financial Officer of Corbus Pharmaceuticals. "We believe that trading on NASDAQ will serve to raise the visibility of Corbus, enhance trading liquidity and broaden our shareholder base as we initiate our upcoming clinical studies with Resunab."

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, added, "Last month we achieved an important regulatory milestone having received clearance for our Investigational New Drug (IND) application for Resunab from the U.S. Food and Drug Administration. This IND enables us to proceed as planned with the initiation of our Phase 2 clinical study in diffuse cutaneous systemic sclerosis (scleroderma) and the submission of a Phase 2 protocol for the treatment of cystic fibrosis in the second quarter of 2015."

About Resunab™
Resunab™ is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 clinical studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models of inflammation and fibrosis. Resunab binds to the CB2 receptor on immune cells and triggers a process known as "inflammatory resolution," in effect turning chronic inflammation "off."

About Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory-fibrotic diseases with clear unmet medical needs. Our lead product candidate, Resunab™, is a novel oral specialized pro-resolving mediator anti-inflammatory drug scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis and diffuse cutaneous systemic sclerosis (scleroderma) in 2015. For more information, please visit www.CorbusPharma.com.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
Investor Contact
Jenene Thomas
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
Phone: [phone]
Email: Email Contact

Media Contact
David Schull or Marissa Goberdhan
Russo Partners, LLC
Phone: [phone]
Email: Email Contact or Email Contact

[MikeDDKing]

LLDTF to uplist

http://www.sec.gov/Archives/edgar/data/1160106/000095010315002886/dp54552_8a12b.htm

[creede]

eses : nice. i noticed that otcmarkets is touting a lot of uplists now-a-days.

Exchange Graduation, “Venture Exchanges” and Optimizing Public Markets for Small Companies

A Message from OTC Markets Group CEO Cromwell Coulson

Last year was a record ‘Exchange Graduation’ year with 83 companies up-listing from our OTCQX, OTCQB and OTC Pink marketplaces to a NYSE, NASDAQ or NYSE MKT listing. In the past five years, more than 400 companies have graduated from our marketplaces to an exchange listing.

http://web.otcmarkets.com/exchange-graduation-venture-exchanges-and-optimizing-public-markets-for-small-companies/?&t=12093

[MikeDDKing]

Eco-Stim Energy Solutions Announces Approval for Listing on NASDAQ

HOUSTON and NEUQUEN CITY, Argentina, April 6, 2015 (GLOBE NEWSWIRE) -- Eco-Stim Energy Solutions, Inc. (ESES) ("EcoStim" or the "Company") announced today that it has received confirmation that its application to list the company's common stock on the NASDAQ Capital Market has been approved by The NASDAQ Stock Market, a unit of the NASDAQ OMX Group.

EcoStim's common stock is expected to begin trading on the NASDAQ Capital Market at the opening of trading on April 10, 2015 under the ticker symbol, ESES. The Company's common stock will continue to trade on the Over-the-Counter Bulletin Board until the market close on April 9, 2015 under the ticker symbol, ESES.

J. Chris Boswell, CEO of EcoStim stated, "Our listing on the NASDAQ is a major milestone for EcoStim and a testament to the tremendous progress we have made over the past year. We believe that the NASDAQ listing will help broaden our shareholder base and provide better liquidity for all shareholders. We continue to believe that the emerging shale oil and gas basins around the world, and in particular the Vaca Muerta shale play in Argentina, offer investors a unique growth opportunity."

EcoStim has established a meaningful presence in this region, offering well stimulation, coiled tubing, and field management services to an expanding customer base in Argentina. This technology platform offers customers an approach that reduces the ecological impact on communities while at the same time reducing cost.

Boswell went on to say, "We feel our approach is especially important in lower commodity price environments as operators focus on more economical and ecological solutions to their drilling and completion programs. However, in Argentina where oil and gas prices are substantially above the prices being realized in the US and other parts of the world, the oil and gas development activity level remains strong which offers those companies participating in the local market the opportunity to grow. At EcoStim, we will continue to identify other undersupplied regions of the world where we can offer our technology and services while creating shareholder value."

About the Company

Eco-Stim Energy Solutions is an environmentally focused oilfield service and technology company providing proprietary field management technologies and well stimulation and completion services to oil and gas producers drilling in the rapidly expanding international unconventional shale market. EcoStim's proprietary methodology and technology offers the potential to decrease the number of stages stimulated in shale plays through a unique process that predicts high probability production zones while confirming those production zones using the latest generation down-hole diagnostic tools. In addition, EcoStim offers its clients completion techniques that can dramatically reduce horsepower requirements, emissions, surface footprint and water usage. EcoStim seeks to deliver well completion services with better technology, better ecology and significantly improved economics for unconventional oil and gas producers worldwide.

Forward-Looking Statements:

The foregoing contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by the Company based on management's experience, expectations and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of performance. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contact:
Jeffrey Freedman, Investor Relations
[e-mail]
281-531-7200

[dadmz]

AEMD is going through a reverse split in preparation for uplisting to NASDAQ. Very high potential biotech company. The CEO stated earlier this year that uplisting in 2015 was a goal and the process just got started.

[accipiterr]

SLTD is uplisting to nasdaq, they will start trading on the exchange wednesday 3/4/2015(tomorrow)